Don’t invest unless you’re prepared to lose all the money you invest. This is a high‑risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more.

Screenshot 2024 06 06 at 15 46 32

TRIMTECH Therapeutics joins Start Codon

We're pleased to welcome TRIMTECH Therapeutics to the Start Codon portfolio.

TRIMTECH’s unique technology was created by the founders in the MRC Laboratory of Molecular Biology and the UK Dementia Research Institute within the University of Cambridge.

Neurodegenerative diseases affect more than 50 million people worldwide and are now the leading cause of death for both men and women in the UK. These diseases, which include Alzheimer’s and Huntington’s, are caused by protein aggregation inside cells.

TRIMTECH's unique technology targets and degrades aggregated proteins, without affecting non-aggregated forms, offering a solution that is both potent and able to demonstrate outstanding safety.

Find out more about TRIMTECH on the portfolio page of our website: